Lupus

Betting on Benlysta, GSK nails down $3.6 billion HGS deal

Betting on Benlysta, GSK nails down $3.6 billion HGS deal

By

GlaxoSmithKline is buying Human Genome Sciences for $3.6 billion, giving it full ownership of Benlysta, along with albiglutide and darapladib, after months of M&A intrigue.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.